Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor.
Cai Y, He J, Wu Z, He W, Dai X, Xu Y, Cheng M, Yang N, Ren Y, Wang G, Wang J, Sai Y, Jia H, Dai G, Li X, Su W.
Cai Y, et al. Among authors: sai y.
J Pharmacol Exp Ther. 2024 Jan 2;388(1):156-170. doi: 10.1124/jpet.123.001752.
J Pharmacol Exp Ther. 2024.
PMID: 37918855